The Marginal Decade: How Founders Can Design Their Best Years
You have a business plan. A succession plan. Possibly an estate plan. The one plan most founders never build is
The Sleep Debt That’s Costing You More Than You Think
Across the business world, sleep deprivation is quietly accepted as a proxy for commitment. The science says something different: it’s
The Highest-ROI Investment a Business Owner Can Make (It’s Not in Your Portfolio)
If exercise existed as a pharmaceutical compound, it would be the most prescribed drug in history. It is also the
The Four Horsemen: The Risks Living in Your Body That No Dashboard Is Tracking
Most business owners have real-time visibility into their company’s cash position, pipeline health, and key risks. Almost none of them
Medicine 3.0: Why Smart Business Owners Are Rethinking Health
The most successful founders plan five years ahead in business. Most of them plan zero years ahead in their body.
Where Deals Will Accelerate: Subsectors Expecting an M&A Surge and Valuation Growth in 2026
1. Introduction: A Market in Active Recomposition The MedTech and healthtech M&A market entered 2026 with structural momentum that has
The Internet of Medical Things (IoMT) as the Foundation of the Smart Clinic and Remote Monitoring
1. Introduction: The Connected Healthcare Ecosystem The “smart clinic” — a healthcare facility where patient data flows seamlessly between devices,
Digital Therapeutics and mHealth: The Shift to Continuous, Behavior-Based Interventions
1. Introduction: From Episodic Care to Continuous Intervention The traditional model of healthcare operates on an episodic architecture: patient experiences
The Convergence of Biotech and Digital Health: Where Deal Boundaries Are Being Redrawn
1. Introduction: When Categories No Longer Hold Investment categories in healthcare were built for a world that no longer exists.
AI Drug Discovery and Organ-on-a-Chip: How Investors Enter the Sandbox Between Pharma and MedTech
1. Introduction: The Preclinical Revolution Drug development has a well-documented efficiency crisis. The historical attrition rate of drug candidates —